cbdMD Therapeutics Announces Human Clinical Study In Collaboration With the University of South Carolina
03 Diciembre 2021 - 8:30AM
Business Wire
cbdMD, Inc. (NYSE American: YCBD, YCBDpA) (the “Company”), one
of the leading, and most highly trusted and recognized cannabidiol
(CBD) brands, announced today that it has commenced a preclinical
human study with researchers at the University of South Carolina.
The study will explore the effects of cbdMD’s proprietary broad
spectrum cannabinoid blend on sleep, mood, and pain in healthy
subjects to further support the efficacy of the Company’s products.
The studies will also be measuring key safety markers in healthy
humans to augment the Company’s safety dossiers for regulatory
submissions. The Company anticipates that these favorable outcomes
will be the basis for future drug research and applications by its
therapeutics division.
“This partnership reaffirms to our consumers that cbdMD is
committed to providing products that make a real impact on their
daily lives. We expect that this study will not only reaffirm that
our products are safe and efficacious to support and maintain a
healthy lifestyle but will also serve as the foundation for future
work to explore the clinical impact of our broad-spectrum
cannabinoid blend on areas that matter most to our customers. We
want to educate our customers on the benefits of our products and
this study will serve as the foundation for that education. This
study is another example of our commitment to safety, quality and
efficacy for our customers,” said Sibyl Swift, Ph.D., cbdMD’s Vice
President, Scientific & Regulatory Affairs.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most highly trusted and
most recognized cannabidiol (CBD) brands with a comprehensive line
of U.S. produced, THC-free1 CBD products. The cbdMD brand currently
includes over 130 SKUs of high-grade, premium CBD products
including CBD tinctures, CBD gummies, CBD topicals, CBD capsules,
CBD bath bombs, CBD bath salts, CBD sleep aids, CBD drink mixes and
full spectrum CBD options. Our Paw CBD brand of pet products
includes over 45 SKUs of veterinarian-formulated products including
tinctures, chews, topicals products in varying strengths, and our
CBD Botanicals brand of beauty and skincare products features 15
SKUs, including facial oil and serum, toners, moisturizers, clear
skin, facial masks, exfoliants and body care. The company also
offers a line of full spectrum products (approximately 10 SKUs)
under its cbdMD brand. To learn more about cbdMD and their
comprehensive line of U.S. grown, THC-free1 CBD oil products,
please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook,
or visit one of the 6,000 retail outlets that carry cbdMD
products.
Forward-Looking Statements
This press release contains certain forward-looking statements
that are based upon current expectations and involve certain risks
and uncertainties within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements can
be identified by the use of words such as ''should,'' ''may,''
''intends,'' ''anticipates,'' ''believes,'' ''estimates,''
''projects,'' ''forecasts,'' ''expects,'' ''plans'' and
''proposes.'' These forward-looking statements are not guarantees
of future performance and are subject to risks, uncertainties, and
other factors, some of which are beyond our control and difficult
to predict and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements,
including, without limitation, statements made with respect to the
expansion of the consumer market for CBD products, our ability to
increase our market share, the availability of the Amazon platform
for our CBD products, our ability to expand our business and
significantly increase our revenues, our ability to effectively
leverage our brand partnerships and sponsorships, our ability to
effectively compete in our market, our ability to achieve our net
sales guidance, and our ability to report profitable operations in
the future. You are urged to carefully review and consider any
cautionary statements and other disclosures, including the
statements made under the heading "Risk Factors" in cbdMD, Inc.'s
Annual Report on Form 10-K for the fiscal year ended September 30,
2020 as filed with the Securities and Exchange Commission (the
"SEC") and our other filings with the SEC. All forward-looking
statements involve significant risks and uncertainties that could
cause actual results to differ materially from those in the
forward-looking statements, many of which are generally outside the
control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc.
does not undertake any duty to update any forward-looking
statements except as may be required by law. The information which
appears on our websites and our social media platforms, including,
but not limited to, Instagram and Facebook, is not part of this
press release.
1THC-free is defined as below the level of detection using
validated scientific methods.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211203005299/en/
PR: cbdMD, Inc. Robert Pettway Director of Public
Relations rpettway@cbdmd.com (423) 503-5225
Investors: cbdMD, Inc. John Weston Director of Investor
Relations john.weston@cbdmd.com (704) 249-9515
cbdMD (AMEX:YCBD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
cbdMD (AMEX:YCBD)
Gráfica de Acción Histórica
De May 2023 a May 2024